{"name":"ImmunityBio, Inc.","slug":"immunitybio-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"ALT-803","genericName":"ALT-803","slug":"alt-803","indication":"Relapsed or refractory acute myeloid leukemia (AML)","status":"phase_2"},{"name":"Aldoxorubicin HCl","genericName":"Aldoxorubicin HCl","slug":"aldoxorubicin-hcl","indication":"Solid tumors","status":"phase_2"},{"name":"M-CENK","genericName":"M-CENK","slug":"m-cenk","indication":"Metastatic solid tumors","status":"phase_2"},{"name":"NAI + Nivolumab + Ipilimumab","genericName":"NAI + Nivolumab + Ipilimumab","slug":"nai-nivolumab-ipilimumab","indication":"Metastatic melanoma","status":"phase_3"},{"name":"NAI + Pembrolizumab","genericName":"NAI + Pembrolizumab","slug":"nai-pembrolizumab","indication":"Advanced or metastatic solid tumors (Phase 3 evaluation)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Lovaza","genericName":"Lovaza","slug":"lovaza","indication":"Other","status":"marketed"},{"name":"Anktiva","genericName":"Anktiva","slug":"anktiva","indication":"Other","status":"marketed"},{"name":"CD19 t-haNK- IV Administration","genericName":"CD19 t-haNK- IV Administration","slug":"cd19-t-hank-iv-administration","indication":"Relapsed or refractory B-cell malignancies","status":"phase_2"}]}],"pipeline":[{"name":"Lovaza","genericName":"Lovaza","slug":"lovaza","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ALT-803","genericName":"ALT-803","slug":"alt-803","phase":"phase_2","mechanism":"ALT-803 is an IL-15 superagonist that stimulates the expansion of natural killer cells and CD8+ T cells.","indications":["Relapsed or refractory acute myeloid leukemia (AML)","Relapsed or refractory multiple myeloma"],"catalyst":""},{"name":"Aldoxorubicin HCl","genericName":"Aldoxorubicin HCl","slug":"aldoxorubicin-hcl","phase":"phase_2","mechanism":"Aldoxorubicin HCl is a prodrug that selectively releases doxorubicin in acidic environments, such as tumor cells, to exert its cytotoxic effects.","indications":["Solid tumors"],"catalyst":""},{"name":"Anktiva","genericName":"Anktiva","slug":"anktiva","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CD19 t-haNK- IV Administration","genericName":"CD19 t-haNK- IV Administration","slug":"cd19-t-hank-iv-administration","phase":"phase_2","mechanism":"CD19 t-haNK- is a type of immunotherapy that targets and kills cancer cells by harnessing the power of a patient's own immune system.","indications":["Relapsed or refractory B-cell malignancies"],"catalyst":""},{"name":"M-CENK","genericName":"M-CENK","slug":"m-cenk","phase":"phase_2","mechanism":"M-CENK is a cancer immunotherapy that targets the CD47/SIRPα axis.","indications":["Metastatic solid tumors"],"catalyst":""},{"name":"NAI + Nivolumab + Ipilimumab","genericName":"NAI + Nivolumab + Ipilimumab","slug":"nai-nivolumab-ipilimumab","phase":"phase_3","mechanism":"This triple combination enhances anti-tumor immunity by activating natural killer cells (NAI), blocking PD-1 checkpoint inhibition (Nivolumab), and blocking CTLA-4 checkpoint inhibition (Ipilimumab).","indications":["Metastatic melanoma","Advanced renal cell carcinoma","Other solid tumors (Phase 3 evaluation)"],"catalyst":""},{"name":"NAI + Pembrolizumab","genericName":"NAI + Pembrolizumab","slug":"nai-pembrolizumab","phase":"phase_3","mechanism":"NAI is a cGAS-STING agonist that activates innate immune signaling, combined with pembrolizumab, a PD-1 checkpoint inhibitor, to enhance anti-tumor immune responses.","indications":["Advanced or metastatic solid tumors (Phase 3 evaluation)","Melanoma and other checkpoint inhibitor-responsive cancers"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPMHFaRjl2UHFWa3J4bzBUaU4tOU1SaWJMWmNrbURIa1pCaUtaTTBCQm9YQzdURkJnU0V3eTI0QTM3ZUVuRGtwdzdhYmV4T1IxM3pBbGYwZUY2R1MwWjF2VjlUNTZLOExPajBtdFF2QzhXRWd2UHZsLS1haTB1MDJpUkJ4bmpwbG5LNlRzUkxveXhLMlpfSkFWOVpYYlhHcnhN?oc=5","date":"2026-03-31","type":"pipeline","source":"The Business Journals","summary":"Dunkirk pharma plant prepares to hire 100, kick off production - The Business Journals","headline":"Dunkirk pharma plant prepares to hire 100, kick off production","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNNGh1OHFEWjBGNkhVU2FFMTRSaUIxWDMzbnBGWGlnclFVSUttekF4ODRqVjVGYm9oVTl3QU9wb0JvSzU5cVB2aUZ4OHN4bVNzaXJzc0FtVWcwdDJNR2hmbV9OTnhGcGV0MWdLMkpucy1mamZFLXFOUjBZUDIxSEFtVzM3RlZmMmhMbFd0cU9EYVlCNENZeld5X0d5cXZDVWNXQTFrcGRITEtMTjhET2xWYTNIaWgzM28?oc=5","date":"2026-03-31","type":"pipeline","source":"The Pharma Letter","summary":"ImmunityBio strengthens balance sheet to fund Anktiva commercialization - The Pharma Letter","headline":"ImmunityBio strengthens balance sheet to fund Anktiva commercialization","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOS3hndDNrNnF6TGZ5ci0zVzBrNjhxSENmclpzZ2p2ZkVrNW1mcGFteTlqRW80cXdjRlJEOTJ2bVBsbk1MWGFDVnNkR2JhMGlDVVRGT1g0LTVDZ18zOFBUblZOWkVNejRmZXFOa0JKR3JGT2hzZ3pvcDllbjd2aWJYOEpkcGtpbEVLeHlYbUtaTWhMYVVpSzFQcg?oc=5","date":"2026-03-25","type":"regulatory","source":"Pharmaceutical Executive","summary":"FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement - Pharmaceutical Executive","headline":"FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxQZDRndVFsaUkxdENnbE1TN0J3N183ZUMzT1AxbnhrVHJKbjFUblZETjhrRFNSeFRaMV9WSWp1QUpCNnM5MmpweXhMMElCdE9PUTY2QjMxSThlekM4ekpyRlYyNlJxSFR6LS00YUlQS2l2RVFFSWxzdl8tV2RjV2wtYXJCaVMtZkVMNXdhQUJSWGRaMHEwREpJLVRyVnZCNUNYTzUwenJzekRHbzFHcnJhbklYdmFHRnhYbUVSZjdZUEh5MnpCNmU5NlVEZW5XbUpCVE1CU1B1OHVWeVJ0cHc?oc=5","date":"2026-03-22","type":"regulatory","source":"BioPharma APAC","summary":"ImmunityBio Secures Macau Approval For ANKTIVA In BCG Unresponsive Non Muscle Invasive Bladder Cancer - BioPharma APAC","headline":"ImmunityBio Secures Macau Approval For ANKTIVA In BCG Unresponsive Non Muscle Invasive Bladder Cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxNQmZ0VW43VHM4R1dRSnhPQnRudklGN3RBT0s3dDVTUWEtUWdKTmZnWE1ZbU9GZEJSMGdhS0h1ODJXMDhaLXI4MVdYUm5Xdm9sd1FQU3VaRlQ2QTFBRDNnNDBKdS1GaG9WbmY3WVZERlROeVNxaWwzd3NxczlOYzl0OHQ1SkdTSHg1MUhhREROMk5VR2JROVZkbVpJWVdlZ1pjWVhkTFNnZHgwZVREeTFDNUxyNGtEOHFWVDdlTlFyZGpoUQ?oc=5","date":"2026-03-17","type":"pipeline","source":"TradingView","summary":"Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026? - TradingView","headline":"Will Anktiva Continue to Drive ImmunityBio's Top-Line Growth in 2026?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPM0xYTE1zU0dKU01IdGt2dE9SM09fWi1xRVEwVWdtT0J4eXRpempXXzVZVDdyOGxnS29Sd04tN0RXcnhQaGhsU1AyQ3BqQmI3UXMyY2Rza0I3ZHdYa0MxS1RERWc2Y2hPNkE0WWdQRWdGdzJlc0xCS3l4N0lVZjVoc3YwNjg1M24ybk1CNTlXOFZVTi1lWFVBNHotcVM5blQ5QXV2QTRldlFpbFBJTkI4bG54c0lYRVZhN1RPYjNGelBBTlNaZEtIbW10N1drREJ4bHptQw?oc=5","date":"2026-03-06","type":"regulatory","source":"Stocktwits","summary":"IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva - Stocktwits","headline":"IBRX Founder’s ‘Congrats’ To GSK Sparks Debate After FDA Fast Drug Approvals — Retail Slams Big Pharma Bias Over Anktiva","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPUWtUQzJkQUhTR2VnbXNBZFJyTmc0N2phTDV2TzFFem5TWHNvNGQ0Vk1LMm81U1VwR0hCWGxDVkNpeFZ2Q2xSRTlQSEZ0LTllQ1FCQy1KbWc2dHdvR1N5M0VNUW9LLXg0N2VBUEg3cFFSWlFYZTlLY3NwblM4VU04N2I0X3czZw?oc=5","date":"2026-03-05","type":"pipeline","source":"Yahoo Finance","summary":"Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies - Yahoo Finance","headline":"Forget ImmunityBio: This Big‑Cap Pharma Is the Safer Play on Next‑Gen Cancer Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxQY25CRllUR3pseUdIV3I0ZEtPajVTd1RwNFBsLTlKZlROdUJ6RkNwMmlYWDBST3d1b0dOaWpVTXU0S1A2bXYxWFZicXVWSTA4V0RITHNPdkFvY0ZYZFJWSU05VDhVaUxkcDFmSmdzeWJIak43UjVKRk96dVBxRW92SkVhUzFBOXNJa3I2TWdtaUxwZ3VpMzR1Rmh2YUdUcTFjWGxsT0QtYWMwa3NNTEtMNWtCYlhjLUlTT2lGVndxYXl6UXFyZzI3R2NDM3JYU1BSemo0Mm11REIydHd3TW51OFZZX3QtTUlOS1RkNkZwOWRRU1ZtWkY3SGdRc1drUQ?oc=5","date":"2026-02-23","type":"earnings","source":"Sahm","summary":"ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday - Sahm","headline":"ImmunityBio Posts Upbeat Q4 Earnings, Joins Arcellx, Vanda Pharmaceuticals And Other Big Stocks Moving Higher On Monday","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxQcTJpMmYzOEsya3VSOXRJelVqOFZEaERHS0lOOVVhc19nNFJZZ2h1M3NaTUpycjFiRkNVT2kzMkpzNjRCQXJoTDZFVjVZSVQ3bmtrTEhtamhVSURkM3J0V1phclR0aElOWU1kRmJoVHc1dVFLQkd6MnhkQXF6QzZoY3UtRTBqMkVuYWdJWm0zQ0RuTkp6amxZSjMxeENZbklQQzBwbXhpbDhvbmgybWI2QUJpd182ZHpYTXplZHI5QmZUSmFUM3pjYVlLZE1MMFExaHI3a0tJNkw0ekRONjRaSkJrSTZQMVNqdFQyY0ZqNDBDR0R2YnVnYzVTeHh1UDBFdHg2T0hxdWxZWGg3QUlyNnFCR08?oc=5","date":"2026-02-20","type":"deal","source":"businesswire.com","summary":"ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients - businesswire.com","headline":"ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOR3lWdTVVZ3hVSkF2NDBRUWpCcHRZbEVfZ01ZblV2YlVWcXQwdkExbmw1dEdhdXJPdmVDSVFRWGpUOXZiZTVRYmZtdlBBODJtcWQ4S0RmY2JOX1dHZXZIdVA1X3VXaEwxaGloRElXbUtuZTI0SUJJTkdfMHJaY2poUUNpMDZwb1A1?oc=5","date":"2026-01-21","type":"regulatory","source":"pharmaphorum","summary":"ImmunityBio rises as route opens to broader Anktiva label - pharmaphorum","headline":"ImmunityBio rises as route opens to broader Anktiva label","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNNGFuNzJ6SlhaVG9yNm9XWGhhYjg2TE5yOTVRSlMxSWNrNHRDOFpMMUpfN0c3Tmo3R0o0blhabjB0cDZVTURudUpzR3hNcVN4cVlQM1pLbjJHNXdwdE5VdnZGWWEwQkhYTmlCTGljTWZWX25zaHlVNndLZWhENDYzdnhUaENDeGtfaGdfTzZBc3pCaDVfY2tyeVR0ZEtxcnZJM2V5MUVfOHJ4ekJ5NDkySg?oc=5","date":"2026-01-15","type":"regulatory","source":"Fierce Pharma","summary":"FDA chides BeOne, ImmunityBio promo materials in 1st untitled letters of 2026 - Fierce Pharma","headline":"FDA chides BeOne, ImmunityBio promo materials in 1st untitled letters of 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOOTJaR013eFRQSFJnU3Zlb0ltaGRxVWJiMnVJckcxc1lGbGxSeThYckNrUDZLOG5vYXB1ajdVSFZOVnJLb2xVNFpzc0RpSEFzMllyRlRJbERzdDBMbVNKdEdNMHRPbXJTSzRycW5XQ0JLX0phZDhONVhaMFBMT2VlUmVhaVRrY1NYYW9oSjFxZWNjS1ZETHQ5NHBDOWtoN1hGV093b3drTGUxQmNMNU9rQUZrRQ?oc=5","date":"2025-12-17","type":"trial","source":"The Pharma Letter","summary":"ImmunityBio reports encouraging 3-year bladder cancer treatment data - The Pharma Letter","headline":"ImmunityBio reports encouraging 3-year bladder cancer treatment data","sentiment":"neutral"}],"patents":[],"drugCount":8,"phaseCounts":{"marketed":2,"phase_2":4,"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}